New Approval for Relapsing Forms of MS Tops SPT Week in Review
Top news of the week from Specialty Pharmacy Times.
5. Cellular Respiration Significantly Increases in Patients with Primary Immunodeficiency Disorders
Metabolic activity in the immune cells of patients with primary immunodeficiency was used as a biomarker due to cellular metabolism, which serves as a key regulator in immune cells.
4. Combo Therapy Shows High Response Rate in Unfit AML Patients With Certain Biomarker
An ongoing phase 2 study is evaluating SY-1425 plus azacitadine in newly-diagnosed unfit patients with acute myeloid leukemia.
3. AI Could Improve Treatment for Crohn Disease
A new computer method could help reveal the origins of Crohn disease and improve early diagnosis and accuracy.
2. FDA Report: Changes in Marketplace Needed to Mitigate Drug Shortages
The FDA Drug Shortages Task Force addressed the root causes of drug shortages and proposed potential solutions.
1. FDA Approves Diroximel Fumarate for Relapsing Forms of Multiple Sclerosis
Patients in a phase 3 study reported better gastrointestinal tolerability with diroximel fumarate (Vumerity) compared with dimethyl fumarate (Tecfidera) in patients with relapsing forms of multiple sclerosis.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
IVIG Therapy Reduced Infections by 67% in Patients With Multiple MyelomaSeptember 19th 2025
